title: Peptide vaccines in cancer-old concept revisited.
abstract: Synthetic peptide vaccines aim to elicit and expand tumor-specific T cells capable of controlling or eradicating the tumor. Despite the high expectations based on preclinical studies, the results of clinical trials using peptide vaccines have been disappointing. Thus, many researchers in the field have considered peptide vaccines as outdated and no longer viable for cancer therapy. However, recent progress in understanding the critical roles of immune adjuvants, modes of vaccine administration and T cell dynamics has lead to a rebirth of this approach and reconsidering the use of peptide vaccines for treating malignant disorders.
authors.affiliation: Cancer Immunology, Inflammation and Tolerance Program, Georgia Cancer Center, Augusta University, Augusta, GA, United States; Department of Pathology, Asahikawa Medical University, Asahikawa, Japan; Department of Otolaryngology, Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan; Department of Innovative Research for Diagnosis and Treatment of Head & Neck Cancer, Japan.
authors.forename: Takumi
authors.initials: T
authors.lastname: Kumai
authors.affiliation: Department of Pathology, Asahikawa Medical University, Asahikawa, Japan.
authors.forename: Hiroya
authors.initials: H
authors.lastname: Kobayashi
authors.affiliation: Department of Otolaryngology, Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan.
authors.forename: Yasuaki
authors.initials: Y
authors.lastname: Harabuchi
authors.affiliation: Cancer Immunology, Inflammation and Tolerance Program, Georgia Cancer Center, Augusta University, Augusta, GA, United States. Electronic address: ecelis@augusta.edu.
authors.forename: Esteban
authors.initials: E
authors.lastname: Celis
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D010455:Peptides / Q000276:immunology / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000276:immunology* / Q000473:pathology
chemical_list: D000276:Adjuvants, Immunologic; D019496:Cancer Vaccines; D010455:Peptides